Review
doi: 10.1007/978-1-4684-5206-8_45.
Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism
- PMID: 3031946
- DOI: 10.1007/978-1-4684-5206-8_45
Item in Clipboard
Review
Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism
Adv Exp Med Biol.
1986.
No abstract available
Similar articles
-
Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.J Clin Invest. 1985 Nov;76(5):1851-6. doi: 10.1172/JCI112178. J Clin Invest. 1985. PMID: 2997292 Free PMC article.
-
In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.J Pharmacol Exp Ther. 1986 Sep;238(3):969-73. J Pharmacol Exp Ther. 1986. PMID: 3018229
-
Dual effects of a new hypocalcemic agent, WR-2721, on cytoplasmic Ca2+ and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism.Biochem Pharmacol. 1986 Dec 1;35(23):4237-41. doi: 10.1016/0006-2952(86)90701-x. Biochem Pharmacol. 1986. PMID: 3024645
-
Bisphosphonates and primary hyperparathyroidism.J Bone Miner Res. 2002 Nov;17 Suppl 2:N150-3. J Bone Miner Res. 2002. PMID: 12412793 Review.
-
Management of hypercalcemia in relation to pathophysiology.Bone. 1987;8 Suppl 1:S29-33. Bone. 1987. PMID: 2825740 Review.